Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roll-over study of sabatolimab with azacitidine and venetoclax in MDS and CMML (Japan)
jRCT2021240013Active, not recruiting
- Sponsor
- Novartis
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Open-label, single-arm trial of sabatolimab in myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML), sponsored by Novartis. Primary endpoint: Frequency and severity of AEs and SAEs. Started Jul 2024; status: active, not recruiting.
02
Drugs
sabatolimab
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on jRCT2021240013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021240013.